Tracking tool is launched on the first parvovirus awareness day DVM 360
View original post here:
Tracking tool is launched on the first parvovirus awareness day - DVM 360
TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.
Read the original post:
Faron Confirms Plans for the Coming Months Under New Leadership
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps
See more here:
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors
Continue reading here:
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Basel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with IgE-mediated food allergy. People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”). Xolair should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterised by the rapid onset of symptoms following exposure to certain food allergens.3 Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies. Xolair is widely available and can now be prescribed for appropriate patients with IgE-mediated food allergy in the U.S.
Read the original here:
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy
Continue reading here:
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
Legislation seeks to bar life insurance companies from purchasing recreational genetic testing data Delaware First Media
Originally posted here:
Legislation seeks to bar life insurance companies from purchasing recreational genetic testing data - Delaware First Media
Boy born deaf can hear for the first time thanks to a gene therapy procedure NBC 6 South Florida
See the rest here:
Boy born deaf can hear for the first time thanks to a gene therapy procedure - NBC 6 South Florida
11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough IFLScience
Here is the original post:
11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough - IFLScience
Gene therapy allows 11-year-old boy to hear for the first time - Latest From ITV News ITVX
Here is the original post:
Gene therapy allows 11-year-old boy to hear for the first time - Latest From ITV News - ITVX
Gene therapy breakthrough enables deaf boy to hear for the first time The Week
Visit link:
Gene therapy breakthrough enables deaf boy to hear for the first time - The Week
Center for Inherited Blood Disorders Administers Country's First Gene Therapy Infusion to Treat Hemophilia A Business Wire
Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... Business Wire
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) before and after surgery with curative intent.
Continued here:
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
UChicago Medicine among the first in the country to offer newly approved sickle cell gene therapies UChicago Medicine
GENEFIT, the First-Ever Fitness Technology to Integrate Personal Genetics with Wearable Tracker Data, Launches to ... Fitt Insider
View original post here:
GENEFIT, the First-Ever Fitness Technology to Integrate Personal Genetics with Wearable Tracker Data, Launches to ... - Fitt Insider